USP15 Antibodies

Ubiquitin carboxyl-terminal hydrolase 15 (USP15)

Hydrolase that removes conjugated ubiquitin from target proteins and regulates various pathways such as the TGF-beta receptor signaling, NF-kappa-B and RNF41/NRDP1-PRKN pathways (PubMed:21947082, PubMed:22344298, PubMed:24852371, PubMed:16005295, PubMed:17318178, PubMed:19826004, PubMed:19576224). Acts as a key regulator of TGF-beta receptor signaling pathway, but the exact mechanism is still unclear: according to a report, acts by encouraging deubiquitination of monoubiquitinated R-SMADs (SMAD1, SMAD2 and/or SMAD3), thereby alleviating inhibition of R-SMADs and encouraging activation of TGF- beta target genes (PubMed:21947082).

According to another reports, regulates the TGF-beta receptor signaling pathway by mediating deubiquitination and stabilization of TGFBR1, leading to an enhanced TGF-beta signal (PubMed:22344298). Able to mediate deubiquitination of monoubiquitinated substrates and'Lys- 48'-linked polyubiquitin chains, protecting them against proteasomal degradation.

Gene Information

Human
Gene Name:	USP15
Uniprot:	Q9Y4E8
Entrez:	9958

Family

Belongs to:
peptidase C19 family

Alternative Names

Deubiquitinating enzyme 15; EC 3.1.2.15; EC 3.4.19.12; Gcap18; KIAA0529; KIAA0529ubiquitin carboxyl-terminal hydrolase 15; MGC131982; MGC149838; MGC74854; ubiquitin specific peptidase 15; ubiquitin specific protease 15; ubiquitin thioesterase 15; Ubiquitin thiolesterase 15; Ubiquitin-specific-processing protease 15; Ubp109; UNPH-2; UNPH4; USP15

Molecular Weight

Mass (kDA):
112.419 kDA

Genomic Context

Human
Location:	12q14.1
Sequence:	12; NC_000012.12 (62260340..62416389)

Tissue Specificity

Expressed in skeletal muscle, kidney, heart, placenta, liver, thymus, lung, and ovary, with little or no expression in other tissues.

Subcellular Localizations

Cytoplasm. Nucleus. Mitochondrion.

Diseases

• Malignant Neoplasms
• Neoplasms
• Malignant Neoplasm Of Ovary
• Adenomatous Polyposis Coli
• Polyposis
• Hyperplasia
• Stomach Neoplasms
• Neoplasm Metastasis
• Von Hippel-lindau Syndrome
• Myopathy
• Cardiovascular Diseases
• Tumor Angiogenesis
• Mammary Neoplasms

• Cell Transformation, Neoplastic
• Glioblastoma
• Malignant Paraganglionic Neoplasm
• Diabetes Mellitus
• Brain Neoplasms
• Advanced Malignant Neoplasm
• Hypertensive Disease

Interacting Proteins

• CARD9
• CCDC57
• INCA1
• MAD1L1
• SPDL1

• TRIM21
• URM1

Pathways

• Proteolysis
• Pathogenesis
• Localization
• Drug Resistance
• Notch Signaling Pathway
• Mitosis
• Angiogenesis
• Nuclear Export

• Tissue Homeostasis
• Oncogenesis
• Nuclear Import

PTMs

• Cleavage

• Ubiquitination

• Phosphorylation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/USP15

Best Uses Of The USP15 Marker

This article will be about the USP15 antibody, the primary antibodies that Steven Boster created, and their potential for therapeutic use in acute lymphoblastic leukemia. These antibodies are well-cited and have been validated both by Boster Bio as well as the research community. Boster's primary antibodies have also been validated in Immunohistochemistry, Western Blotting, and ELISA. Listed below are the top three uses of the USP15 antibody.

His primary antibodies were highly cited

Boster Bio is a top-ranked manufacturer of primary antibodies. To create the list, Boster Bio conducts a systematic manual study of more than 60000 randomly selected publications. The list contains all suppliers whose products have been cited at least once. The list shows the five most popular products for each supplier. It also includes high-quality suppliers who do not have any citations.

The primary antibodies for the company are mouse IgG1 (goat anti-rabbit IgG1) and rabbit anti-mouse IgG1. The two most frequently cited antibodies are rabbit anti–mouse IgG1and goat anti–mouse IgG1. The company also offers a wide range of monoclonal and polyclonal antibodies. Some of these products are cited as highly as 4,000 articles! Research will be more efficient if you use boster Bio's antibodies.

His work is a therapeutic option in acute myeloidleukemia

Cold Spring Harbor Laboratory scientists identified a potential therapeutic target to treat acute myeloid leukaemia, a disease where white blood cells multiply uncontrollably within the bone marrow. Scientists were able halt the disease’s uncontrolled growth in mice by blocking PRC2, which is a protein that regulates the growth of white blood cells.